NASDAQ
12.37USD
-1.65 (-11.77%)
We have scored 6 news catalysts on Cybin Inc. Common Stock (HELP) over the past 12 months. The biggest single-day move next to one of them came Jul 21, 2026, when HELP closed +13.9%: “Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule”. Coverage across the window leans positive (average ticker sentiment +0.73). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
766.7M
P/E
—
EPS
—
Beta
0.56
52W range
3.76-15.15
Day range
12.10–15.15
Open
15.15
Prev close
14.02
Volume
5.7M
Avg volume
1.5M
Dividend
0.00
IPO
2019-09-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cybin Inc. Common Stock — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for HELP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
